Getting denied coverage for Humira is stressful enough on its own. If you live with a chronic condition like rheumatoid arthritis, Crohn’s disease, or psoriasis, a denial can feel like a direct threat to your health, especially if you’re already on the medication and staring down a gap in treatment.

If you're reading this, you've already done the most important thing: you know you can appeal, and you're looking for the tools to do it well. A template is a smart place to start. The thing worth knowing is that a template alone isn't usually what wins and appeal. Insurers review thousands of appeal letters, and a generic one that says "my doctor recommends Humira" without specific clinical evidence is easy to deny. The letter that gets approved is the one you tailor with the right details, and that's exactly what this guide is built to help you do.

This guide shows you how to file your own Humira appeal with a letter built to get approved, not just submitted. We’ll walk through the template section by section, explain how to tailor your approach to your specific insurance type, and cover what to do if your first appeal comes back denied.

If you’d rather not navigate this alone, Claimable builds fully customized appeal letters using a purpose-built database of clinical studies, insurer policies, and laws, then mails and faxes them directly to your insurer.

Why Humira Denials Are So Common Right Now

For nearly two decades, Humira had almost no competition. That changed fast. The first adalimumab biosimilar, Amjevita, launched in January 2023, and a wave of others followed that summer, including Cyltezo, Hadlima, and Hyrimoz. With lower-cost alternatives suddenly on the market, pharmacy benefit managers moved quickly to steer their formularies toward biosimilars and away from brand-name Humira.

The most consequential move came from CVS Caremark, one of the largest PBMs in the country, which removed Humira from its major national commercial formularies effective April 1, 2024. Other large PBMs have made similar changes for subsequent plan years. The result is a surge of denials that simply didn’t exist a few years ago, hitting two very different groups of patients: people who are newly prescribed Humira and being told to try a biosimilar first, and people who have been stable on Humira for years and are now being pushed to switch.

Both situations are appealable. The right argument just depends on which denial you’re facing.

The Most Common Reasons for Humira Denials

Before you write a single sentence, find the exact reason your insurer denied coverage. It’s printed on your denial letter, and it determines your entire strategy. Submitting the wrong type of response wastes time and can burn through your limited appeal opportunities.

If your denial came down to something fixable, like missing lab work or screening results that your plan requires before approving Humira, you may not need a full appeal at all. A corrected resubmission with the missing documents attached can sometimes resolve it faster. Our guide to Humira denials breaks down how to match each denial type to the right response.

Humira Appeal Letter: What to Include, Plus a Customizable Template

We’ve put together a free, customizable appeal letter template you can use to appeal your Humira denial. You can download a copy here:

Download the free appeal letter template

Before you download it, here’s an overview of everything a strong Humira appeal should include, and why each section carries the weight it does.

Section 1: Your Information, Their Information, and Claim Details

The letter opens with a header block identifying you, your insurer’s appeals department, and the specific claim being appealed. Follow it with an opening paragraph that names the medication, your prescribing physician, your diagnosis, and the insurer’s stated reason for denial, copied word for word from the denial letter. Matching their exact language matters, because your job in the rest of the letter is to dismantle that specific reason.

If a gap in treatment would harm your health, this is also where you request an expedited review. Many plans are required to decide expedited appeals far faster than standard ones, often within 72 hours.

Section 2: Diagnosis and How It Affects Your Life

Here you lay out your diagnosis, including the ICD-10 code if you have it, any comorbidities, and a specific description of your symptoms and how they affect your daily life. This is the part of the letter that makes the human cost of the denial concrete. A reviewer who reads that you’ve missed work, lost mobility, or can’t care for your family reads the rest of your argument differently.

Section 3: Prior Treatments Tried and Failed

This is where you prove you’ve already satisfied step therapy and prior authorization requirements. Document every medication and treatment you tried before Humira in a simple table:

Specific dates, drug names, and outcomes are what turn “I’ve tried other things” into documented evidence the insurer has to reckon with. If you’re being forced off Humira and onto a biosimilar, this section is also where you note that you were stable on Humira and that switching carries real clinical risk for you.

Section 4: Why This Medication Is Medically Necessary

This section ties together your physician’s recommendation, your clinical profile, and any improvement you’ve already seen on Humira (or expect to see if you haven’t started yet). It should also spell out what happens without it: disease progression, irreversible joint or organ damage, hospitalization risk, or loss of function. Medical necessity is the standard most denials hinge on, so this is where you meet it head-on.

Section 5: Clinical Evidence Supporting This Treatment

This is the most research-intensive section, and the one that separates a strong appeal from a hopeful one. Cite specific clinical studies, professional society guidelines, and the FDA labeling that support Humira for your condition. Name the trials, quantify the outcomes, and connect each piece of evidence directly to the insurer’s stated reason for denial.

One serious warning: never cite a study you haven’t verified. Fabricated or misquoted clinical references do more damage than no citation at all. A reviewer who catches one invented study has every reason to distrust your entire letter. We’ll come back to this, because it’s the single biggest risk in the era of AI-generated appeals.

Section 6: Your Denial Doesn’t Align With Your Insurer’s Own Policies

Insurers publish their coverage criteria for Humira, and those documents are public. Pull your plan’s policy, find the criteria, and demonstrate point by point that you already meet them. There is nothing more persuasive than showing that a denial contradicts the insurer’s own written rules. This is also one of the places where insurers count on patients not looking, because the process is built to be opaque.

Section 7: Applicable State and Federal Law

Citing the law transforms your appeal from a personal request into a legal demand, and insurers handle those very differently. The protections available to you depend on your state and the type of plan you have, but they often include step therapy override laws, prior authorization response-time requirements, ERISA protections for employer plans, ACA guarantees of internal and external appeal rights, and your right to an independent external review.

Step therapy override laws are worth understanding in particular. Most states now have them, and they commonly bar a plan from making you repeat step therapy you’ve already completed, including under a previous insurer, and they often require the plan to accept your prescriber’s attestation that a required drug failed as evidence of that failure. If you’ve already tried and failed the biosimilar your plan is now demanding, that’s not just a clinical argument. In many states, it’s a legal one. Our formulary exception guide covers how to invoke these protections when your drug has been excluded.

Section 8: Request for Review and Approval

Close with a clear, formal request: approve coverage for Humira, override the specific barrier cited in the denial, and, if your treatment is time-sensitive, process the appeal on an expedited basis. Ask for written confirmation of the decision, and if the appeal is denied, request a complete copy of your claim file so you can see exactly what the reviewer considered.

Section 9: Supporting Documentation Enclosed

List everything you’re attaching: your physician’s letter of medical necessity, relevant medical records, the clinical studies you cited, any prior appeal decisions, and lab results. A reviewer should never have to go looking for the evidence that backs your argument.

Section 10: Citations and References

End with a references section listing every study, guideline, insurer policy, and law you cited, formatted so a reviewer can locate each source. This is also your own final check: if you can’t produce a clean citation for a claim, that claim shouldn’t be in the letter.

An Alternative Approach: Use Claimable

The template above gives you the structure of a strong appeal. But the sections that carry the most weight, namely the clinical evidence, the insurer policy analysis, and the legal citations, are also the ones that take hours of research and carry real risk if you get them wrong. A fabricated study or a misapplied law can sink an appeal that would otherwise have won.

Claimable was built to solve exactly this problem. You answer a set of straightforward questions about your denial, diagnosis, and treatment history, and Claimable generates a fully personalized appeal letter drawing on a purpose-built database of clinical studies, insurer policies, and laws. Every citation is verified. Every argument is tailored to your specific insurer and plan type. We’ll even mail and fax it to your insurer for you.

More than 80% of Claimable appeals succeed, with most resolved in 10 days or less, delivering industry-leading results.

Start your appeal with Claimable.

Common Mistakes That Get Humira Appeals Denied

Missing or Incomplete Documentation

The most common reason appeals fail has nothing to do with the strength of the argument. It’s missing paperwork. Patients submit lab results that are too old to satisfy the plan’s screening requirements, forget to include the original denial letter, or list prior medications without the specific dates and dosages that make them count as evidence. Before you send anything, make sure every claim in your letter is backed by a document in the envelope.

Using Vague or Generic Language

“The patient needs this medication” tells a reviewer nothing. Vague appeals fail because they don’t engage with the actual reason for denial and don’t give the reviewer anything specific to approve. The fix is specificity: name your disease activity scores, your failed treatments and why they failed, and the exact clinical reason Humira is right for you. Emotion belongs in your letter, but it supports the evidence rather than standing in for it. Lead with the clinical case and let the personal impact reinforce it.

Missing the Deadline

Deadlines are unforgiving, and missing one can cost you your appeal rights entirely. Under the ACA, plans generally must give you at least 180 days from the date of your denial to file an internal appeal, and 4 months after a final internal denial to request an external review. But the specifics vary by plan type and state. ERISA employer plans, Medicare, and Medicaid each run on their own timelines, and some are considerably shorter. Expedited appeals have tighter windows still. The safest move is to mark your calendar the day your denial arrives and file as early as you can, while your documentation is freshest. Your exact deadline is printed on your denial letter.

Citing Inaccurate Information

This is the fastest-growing way to lose an appeal, and it’s worth dwelling on. General-purpose AI tools and generic template letters can often produce fabricated clinical studies and incorrect legal citations that look completely real. If your appeal references a study that doesn’t exist or a law that doesn’t say what you claim, it doesn’t just fail to help. It damages your credibility and gives the reviewer a clean reason to deny. So, always verify every clinical study and legal reference before it goes anywhere near your insurer.

This is also exactly why Claimable was built differently. Claimable’s proprietary AI runs on a purpose-built database of real clinical studies, real laws, and real policy data, not a general-purpose chatbot guessing at citations. Every appeal is checked before it goes out. Start your appeal.

What to Do If Your First Appeal Is Denied

A first denial is not the end of the road. It’s the first step on a path that has several more, and patients who keep going win far more often than patients who stop. Here’s the full map.

Level 1: Internal Appeal

Your first appeal goes back to the insurer, where it must be reviewed by someone who wasn’t involved in the original decision. Treat a second internal appeal as a chance to strengthen your case rather than simply resubmit it. Address every specific deficiency the insurer cited, add any new clinical evidence or updated records you can gather, and shore up your physician’s letter of medical necessity if the first one was thin. It’s also worth asking your doctor to request a peer-to-peer review, where they speak directly with the insurer’s medical director. For specialty medication denials, these conversations have a strong track record of overturning the original decision.

Level 2: External Review

Once you’ve exhausted internal appeals, you can request an independent external review, where a reviewer who doesn’t work for your insurer evaluates your case. This is one of the most powerful rights you have, and one of the least used. In most plan types, the external reviewer’s decision is binding, meaning the insurer must comply if the denial is overturned. Many states run their own external review processes with their own timelines and procedures, so check the rules where you live.

Level 3: Regulatory Complaints and Other Options

If you’ve worked through internal and external review and still need leverage, you have more options. For state-regulated plans, filing a complaint with your state’s Department of Insurance can add real pressure, and many states have patient advocacy offices or managed care ombudsman programs that can help. For high-value or especially complex cases, a consultation with an attorney who handles insurance disputes may be worthwhile. The system is designed to wear people down. Knowing that these escalation paths exist is often what keeps a winnable appeal alive.

Frequently Asked Questions

How long do I have to appeal a Humira denial?
Under the ACA, plans generally must give you at least 180 days from your denial to file an internal appeal, and 4 months after a final internal denial to request an external review. ERISA employer plans, Medicare, and Medicaid run on their own timelines, some shorter, so always check the deadline printed on your denial letter.

Can I appeal if my insurer dropped Humira from its formulary?
Yes. A formulary exclusion is appealable through a formulary exception request, in which you argue that the covered alternatives are inappropriate for you, often because you’ve already tried and failed a biosimilar or were stable on Humira before the switch was forced. Your plan’s own coverage criteria and applicable step therapy laws are central to this argument.

Do I need my doctor to file the appeal?
No. You have the right to file your own appeal, and patient appeals carry legal protections that provider appeals don’t, including mandated response timelines and external review rights. Your doctor’s letter of medical necessity strengthens your case, and a patient appeal and a provider appeal filed together create pressure from two directions.

What’s the difference between Humira and a biosimilar, and does it matter for my appeal?
Biosimilars are highly similar to Humira and approved to treat many of the same conditions, but “similar” isn’t “identical.” Some patients experience differences in side effects, injection devices, or how well their condition stays controlled. If you’ve had a documented problem on a biosimilar, that experience is important evidence in an appeal to stay on or return to Humira.

Will citing clinical studies and laws really make a difference?
Yes, as long as they’re accurate. Specific clinical evidence and applicable law are what move an appeal from a personal request to a documented, legally grounded demand. Just be certain every citation is real and correctly stated, because a single fabricated reference can sink an otherwise strong appeal.

Don’t Appeal Alone If You Don’t Have To

You have the right to appeal, the law is often on your side, and Humira denials are overturned every day by patients who know how to build their case. The template above gives you the structure to do it yourself.

If you’d rather not spend hours researching studies and verifying legal citations, Claimable handles the hardest parts for you, builds an appeal tailored to your insurer and plan, and submits it on your behalf. More than 80% of our appeals succeed, with most resolved in 10 days or less.

Start your Humira appeal with Claimable.